for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dermira Inc

DERM.OQ

Latest Trade

7.16USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

5.25

 - 

15.47

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.16
Open
--
Volume
--
3M AVG Volume
17.47
Today's High
--
Today's Low
--
52 Week High
15.47
52 Week Low
5.25
Shares Out (MIL)
54.40
Market Cap (MIL)
389.49
Forward P/E
-1.61
Dividend (Yield %)
--

Latest Developments

More

Dermira Announces Initiation Of Phase 3 Program Evaluating Lebrikizumab In Patients With Moderate-To-Severe Atopic Dermatitis

Dermira Says Q2 Revenue of $66.6 Million

Almirall Exercises Its Option With Dermira To License Rights To Lebrikizumab In Europe For Atopic Dermatitis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Dermira Inc

Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.

Industry

Biotechnology & Drugs

Contact Info

275 Middlefield Rd Ste 150

+1.650.4217200

http://dermira.com/

Executive Leadership

Thomas G. Wiggans

Chairman of the Board, Chief Executive Officer, Co-Founder

Luis C. Pena

Co-Founder, Chief Development Officer

Andrew L. Guggenhime

Chief Financial Officer

Christopher Horan

Chief Technical Operations Officer

Christopher M. Griffith

Chief Business and Strategy Officer

Key Stats

1.88 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (USD)

2016

-2.700

2017

-7.480

2018

-5.270

2019(E)

-4.451
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.41
Price To Book (MRQ)
5.94
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
480.32
LT Debt To Equity (MRQ)
480.32
Return on Investment (TTM)
-55.97
Return on Equity (TTM)
-47.32

Latest News

Latest News

BRIEF-Dermira Inc Entered Into First Amendment To License Agreement With Roche

* DERMIRA INC - ENTERED INTO FIRST AMENDMENT TO LICENSE AGREEMENT WITH ROCHE

FDA approves Dermira's wipe for excessive armpit sweating

Dermira Inc <DERM.O> said on Friday its topical cloth for excessive armpit sweating was approved by the U.S. Food and Drug Administration, providing patients with an easy-to-use option for an often embarrassing condition.

Dermira's treatment for excessive armpit sweating gets U.S. approval

The U.S. Food and Drug Administration on Friday approved Dermira Inc's treatment for excessive armpit sweating, providing patients with an easy-to-use treatment option for an often embarrassing condition.

BRIEF-Dermira Says Company's COO Position Was Eliminated

* DERMIRA SAYS COMPANY'S CHIEF OPERATING OFFICER POSITION WAS ELIMINATED, EFFECTIVE AS OF MAY 3, 2018 - SEC FILING Source : https://bit.ly/2Iesp3E Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Dermira Inc Q1 Loss Per Share $1.42

* DERMIRA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Dermira to abandon acne drug, shares crater

Dermira Inc will discontinue development of its acne drug after the treatment failed to meet the main goals of two late-stage studies, the company said on Monday.

Dermira abandons acne drug

Dermira Inc said on Monday it would discontinue the development of its acne drug after it failed to meet the main goals of two late-stage studies.

BRIEF-Dermira's Two Phase 3 Trials Evaluating Olumacostat Glasaretil In Patients With Acne Vulgaris Did Not Meet Co-Primary Endpoints

* DERMIRA’S TWO PHASE 3 TRIALS EVALUATING OLUMACOSTAT GLASARETIL IN PATIENTS WITH ACNE VULGARIS DID NOT MEET CO-PRIMARY ENDPOINTS

BRIEF-Dermira Qtrly Loss Per Share $‍1.34​

* DERMIRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Dermira posts Q3 loss $4.30/shr, says FDA accepts NDA for glycopyrronium tosylate

* Dermira reports third quarter 2017 financial results and announces that FDA accepts new drug application for glycopyrronium tosylate for the treatment of patients with primary axillary hyperhidrosis

BRIEF-Dermira and UCB agree to end collaboration agreement for Cimzia

* Dermira and UCB agree to end collaboration agreement for Cimzia

BRIEF-Dermira highlights new long-term safety data for glycopyrronium tosylate

* Dermira highlights new long-term safety data for glycopyrronium tosylate in primary axillary hyperhidrosis at fall clinical dermatology conference

BRIEF-Dermira completes patient enrollment in two phase 3 trials of olumacostat glasaretil for the treatment of acne vulgaris

* Dermira completes patient enrollment in two phase 3 pivotal trials of olumacostat glasaretil for the treatment of acne vulgaris

BRIEF-Dermira presents new data showing impact of primary axillary hyperhidrosis on patients

* Dermira - presented new patient-reported outcomes data from two Phase 3 clinical trials showing impact of primary axillary hyperhidrosis on patients

BRIEF-Dermira enters into agreement to license exclusive, worldwide rights to Lebrikizumab

* Dermira enters into agreement to license exclusive, worldwide rights to Lebrikizumab

BRIEF-UCB and Dermira announce US and EU regulatory submissions for Cimzia

* UCB AND DERMIRA ANNOUNCE U.S. AND EU REGULATORY SUBMISSIONS FOR CIMZIA (CERTOLIZUMAB PEGOL) FOR THE TREATMENT OF MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS Source text: http://bit.ly/2ty2bhV Further company coverage: (Gdynia Newsroom)

BRIEF-Dermira Inc names Ian Clements VP, Investor Relations

* Dermira announces appointment of Ian Clements as vice president, investor relations Source text for Eikon: Further company coverage:

BRIEF-Dermira prices offering of $250 million of 3 pct convertible senior notes

* Dermira prices offering of $250 million of 3.00% convertible senior notes

BRIEF-Dermira announces proposed offering of $250 mln of convertible senior notes

* Dermira announces proposed offering of $250 million of convertible senior notes

BRIEF-Dermira qtrly net loss per share, basic, diluted $ 0.79

* Dermira reports first quarter 2017 financial results and provides corporate update

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up